On 20 December 2024, the U.S. FDA approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a next-generation combination of CFTR modulators developed by Vertex Pharmaceuticals for cystic fibrosis patients aged 6 years and older with at least one F508del mutation or other responsive mutations [194]. Here, CFTR is linked to cystic fibrosis.